Strong growth reported for Australia's medtech sector
13 February, 2018Australian jobs supported by the medtech, biotech and pharma sector increased by 10% from 2015 to 2016, while manufacturing exports increased by 30%.
Immutep's lead product well tolerated in melanoma trial
12 February, 2018Immutep's lead product has been found safe and well tolerated when combined with pembrolizumab (KEYTRUDA) at doses up to 30 mg per subcutaneous injection.
Electric fields + peptides = better implantable device integration
09 February, 2018Researchers have made a discovery that could help implantable devices better integrate with the body, thus reducing risk of infection.
Protein-based nanoshuttle to deliver anticancer vaccines
07 February, 2018US biomedical engineers are using a natural protein called albumin as a way to 'shuttle' cancer-fighting nanovaccines into the body.
Collaboration to improve outcomes for cochlear implant recipients
29 January, 2018Sensorion and Cochlear have announced a strategic collaboration focused on improving hearing outcomes in patients with cochlear implants.
New drug could halt MS in its tracks
25 January, 2018Monash University researchers are about to conduct a study into a drug that may thwart the progression of multiple sclerosis, following a $70,000 grant from MS Research Australia.
Reform recommended for genetic modification regulations
22 January, 2018Australia's gene technology regulator has proposed reducing regulations around gene editing techniques such as CRISPR, following a 12-month technical review.
One giant LEAP for regenerative medicine
12 January, 2018Exopharm has finalised testing for its disruptive LEAP technology, taking a further step in bringing extracellular vesicles as an acellular therapy to treat patients with degenerative conditions.
Cancer-fighting seaweed
11 December, 2017Animal studies undertaken at UTHealth have shown that the two seaweed extracts — known as fucoidans — have reduced tumour growth in select cancers and significantly improved the effectiveness of the common chemotherapy drug tamoxifen.
Cannabis-based epilepsy drug coming in 2018
07 December, 2017MGC Pharmaceuticals has executed a binding definitive exclusive supply agreement with pharmaceutical wholesaler HL Pharma to bring its adult epilepsy product, CannEpil, to the Australian market in 2018.
Bio-Gene Technology collaborates with CSIRO on insecticide development
01 December, 2017Bio-Gene Technology, a manufacturer of insecticides, has entered into an extended research agreement with CSIRO to develop improved manufacturing systems for its lead product, Flavocide.
Strong anticancer activity identified in newly patented AAD compounds
29 November, 2017PharmAust has been granted a new patent in the US covering its portfolio of anticancer drugs, recently proven to be more effective at killing cancer cells than their parent compound.
Lonza XS Pichia 2.0 Expression and Manufacturing Platform
24 November, 2017Lonza has developed an expression and manufacturing system that provides high product titres (up to 6 g/L) along with a fast, robust and scalable manufacturing process suitable for commercial production. The XS Pichia 2.0 system is said to deliver high cell viability for improved product quality; reduced fermentation times that approximate E. coli processes; and ease of implementation in large-scale plants.
Biotron compounds demonstrate antiviral activity against hep B
17 November, 2017Biotron has announced that several of its compounds have demonstrated significant antiviral activity against hepatitis B (HBV) in recently completed preclinical studies.
Prima BioMed announces positive data, pre-IND meeting for anticancer candidate
16 November, 2017Prima BioMed has presented new data from a phase I clinical trial investigating eftilagimod alpha, its anticancer candidate, in combination with pembrolizumab in unresectable or metastatic melanoma patients.
